By Edward Tobin and Ransdell Pierson
NEW YORK (Reuters) - MERCK (MRK.NY)& Co Inc said on Monday it would acquire SCHERING (SCH.XE)Plough Corp for $41.1 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for big pharma in weeks.
The deal between the New Jersey drugmakers comes amid a harsher climate for pharmaceutical companies, as they have failed to produce enough new drugs to replace old ones, and as the new Obama Administration prepares healthcare reforms that could pressure drug prices.
And it landed the same day Roche Holding AG moved closer to its long sought-after purchase of the remaining stake in Genentech Inc that it doesn't already own, with a source telling Reuters the two sides are discussing a deal for about $46.7 billion.
Schering-Plough's earnings and share price have deteriorated over the past year due to a plunge in sales of Vytorin and Zetia, its biggest products, even as several of its most promising drugs move into very costly late-stage trials.
Merck, which has seen profits and shares battered by Vytorin's decline and other setbacks, has deeper pockets and would help fund research on Schering-Plough products, including promising blood clot and hepatitis C drugs.
"The deal gives Merck more breathing room," said Mehta Partners analyst Viren Mehta, as it girds for patent expirations in 2012 on its $4-billion-a-year Singulair asthma drug and by next year for its Cozaar blood-pressure treatment.
The deal, which many analysts have forecast for years given the Vytorin partnership between Merck and Schering-Plough, follows Pfizer Inc's $68 billion planned purchase of Wyeth. Sanford Bernstein analyst Tim Anderson said it was surprising that Wyeth and Schering-Plough agreed to sell, given their depressed stocks and their robust long-term outlooks.
"What could this imply about how pharma company management teams view the future of the industry?" Anderson said.
The transaction offers a premium of 34 percent for Schering-Plough shareholders based on Friday's closing price and will generate savings of $3.5 billion annually after 2011.
Merck and Schering-Plough, which announced significant job cuts last fall, said about 15 percent of their combined workforce would be eliminated under the deal, with most job cuts to take place outside the United States.
"It seems somewhat inevitable," analyst Jeffrey Holford of Jefferies in London said of the deal, referring to an industry coping with generic rivals as cost cuts have run their course.
"The industry needs to shrink because there is just not the same market for branded pharmaceuticals going forward as there has been over the last 10 years. There is overcapacity and (Merck and Schering-Plough) need to take each other's capacity out of the market."
It will also double the number of experimental medicines Merck has in late-stage development to 18 and diversify Merck's lineup of medicines to include cardiovascular, respiratory, oncology, neuroscience and infectious disease.
Schering-Plough shareholders will receive 0.5767 shares of Merck and $10.50 in cash for each of their shares, valuing each share of Schering-Plough at $23.61.
Schering-Plough investors have reason to feel short-changed, said Caris & Co analyst David Moskowitz.
"I think it should be at least $12 billion to $15 billion higher," he said. "I don't think investors will be happy until the price comes up to the high-$20's or $30 (per share)."
Schering-Plough shares rose 14 percent to $20.25 before the market opened, and was up $2.52, or 14.3 percent, at $20.15 late Monday afternoon. Merck hit a 14-year low of $20.10, before trading down 7.8 percent at $20.96.
Merck's 4.75 percent notes due in 2015 traded weaker, with spreads widening to 149 basis points over Treasuries, yielding 4.4 percent. On March 4, in their last notable trade, the spread was 124 basis points with a yield of 4.2 percent, according MarketAxess data.
ARTHRITIS DRUG RIGHTS IN QUESTION
A big question is whether Merck will inherit Schering-Plough's overseas rights to nearly $2 billion-a-year Remicade and newer arthritis drug golimumab.
Analysts expressed surprise at Merck's confidence it will not have to hand back the arthritis drug rights to Johnson & Johnson under a change of control clause.
Merck, which structured its takeover as a reverse merger that analysts said may give it some leverage to protect the arthritis drugs, said it had not discussed the matter with J&J and that the high-stakes issue would be settled by binding arbitration if J&J throws up a roadblock.
"It is theoretically possible that J&J comes in and bids for Schering-Plough, because the fit between Schering-Plough and J&J would be a good one," said Sanford Bernstein analyst Tim Anderson.
J&J officials declined to comment.
The deal is composed of $9.8 billion in cash, $8.5 billion in financing provided by JPMorgan Chase & Co and $22.8 billion in Merck stock.
Merck Chief Executive Richard Clark, who investors initially considered a caretaker CEO when he took the helm in 2005, will lead the combined company, with Merck shareholders owning a 68 percent stake.
Schering-Plough CEO Fred Hassan, who turned around Pharmacia Corp before selling it to Pfizer Inc, said his plans after the Schering-Plough deal is completed are unclear.
Merck, which vowed to maintain its dividend, expects the deal to close in the fourth quarter and add modestly to operating earnings in the first full year following completion and "significantly" after that.
The combined 2008 revenue of the two companies totaled $47 billion and Merck believes it will maintain its current credit ratings.
Bernstein's Anderson cautioned that such a big company, with combined revenues close to Pfizer's, could have a much harder time delivering earnings growth.
J.P. Morgan acted as financial adviser and Fried, Frank, Harris, Shriver & Jacobson LLP acted as legal adviser to Merck. Goldman, Sachs and Morgan Stanley acted as financial advisers and Wachtell, Lipton, Rosen & Katz acted as legal adviser to Schering-Plough.
(Reporting by Edward Tobin, Ransdell Pierson and Walden Siew in New York and Ben Hirschler in London, Sam Cage in Zurich; Editing by Lisa Von Ahn, Andre Grenon, Richard Chang)
